TP53 loss creates therapeutic vulnerability in colorectal cancer.

• Autores: Yunhu Liu, Xinna Zhang, Cecil Han, Guohui Wan, Xingxu Huang, Cristina Ivan, Dahai Jiang
• Localización: Nature: International weekly journal of science, ISSN 0028-0836, Vol. 520, Nº 7549, 2015, págs. 697-701
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • TP53, a well-known tumour suppressor gene that encodes p53, is frequently inactivated by mutation or deletion in most human tumours 1,2. A tremendous effort has been made to restore p53 activity in cancer therapies 3-7. However, no effective p53-based therapy has been successfully translated into clinical cancer treatment owing to the complexity of p53 signalling. Here we demonstrate that genomic deletion of TP53 frequently encompasses essential neighbouring genes, rendering cancer cells with hemizygous TP53 deletion vulnerable to further suppression of such genes. POLR2A is identified as such a gene that is almost always co-deleted with TP53 in human cancers. It encodes the largest and catalytic subunit of the RNA polymerase II complex, which is specifically inhibited by [alpha]-amanitin 8,9. Our analysis of The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) databases reveals that POLR2A expression levels are tightly correlated with its gene copy numbers in human colorectal cancer. Suppression of POLR2A with [alpha]-amanitin or small interfering RNAs selectively inhibits the proliferation, survival and tumorigenic potential of colorectal cancer cells with hemizygous TP53 loss in a p53-independent manner. Previous clinical applications of [alpha]-amanitin have been limited owing to its liver toxicity 10. However, we found that [alpha]-amanitin-based antibody-drug conjugates are highly effective therapeutic agents with reduced toxicity 11. Here we show that low doses of [alpha]-amanitin-conjugated anti-epithelial cell adhesion molecule (EpCAM) antibody lead to complete tumour regression in mouse models of human colorectal cancer with hemizygous deletion of POLR2A. We anticipate that inhibiting POLR2A will be a new therapeutic approach for human cancers containing such common genomic alterations.